Theralink Technologies, Inc.
OBMP
Other OTC1.56
USD
-0.92
- -
CIK
0001362703
ISIN
US68235A2006
CUSIP
68235A200
Return %
Stock
S&P500
1Y
- -
19.01
3Y
- -
65.48
5Y
41.82
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Full Time Employees
- 16
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 15000 West 6th Avenue Golden CO United States of America 80401
- IPO Date
- Oct 5, 2021
- CIK
- 0001362703
- Website
- theralink.com
- Similar Companies
- Business
- Theralink Technologies, Inc. (OTC: OBMP) operates as a commercial-stage precision medicine and molecular data-generating company focused on phosphoproteomic technologies for oncology. The company develops and commercializes patented Reverse Phase Protein Array (RPPA) assays that measure the activation state of over 600 protein and phosphoprotein drug targets and signaling pathways in tumor tissue; provides laboratory-developed tests and precision oncology data to identify likely responders and non-responders to FDA-approved and investigational therapies; and offers biopharma services for early- and late-stage drug development to accelerate discovery programs, supported by seven patents and over 1,000 peer-reviewed publications on RPPA technology. Theralink targets clinical oncologists, physicians, patients, and biopharmaceutical companies in the United States, with applications across multiple cancer types including breast cancer. Founded in 2005 and headquartered in Golden, Colorado, the company changed its name from OncBioMune Pharmaceuticals, Inc. in September 2020; achieved College of American Pathologists accreditation for its commercial RPPA laboratory in November 2022; partnered with Perthera in November 2020 to expand access to its 32 phosphoprotein panel; signed a definitive merger agreement with IMAC Holdings, Inc. in May 2023 that was terminated in May 2024, resulting in IMAC acquiring Theralink's key assets (excluding certain items) via a settlement resolving outstanding debt, with IMAC transitioning employees to continue commercialization of the precision medicine business.
AMC Is Winning the Keynesian Beauty Contest